CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Sector investing has been given a bad rap .
The crisis gave financial innovation a bad rap . Don't let that stifle fresh thinking, Eyelock's Jeff Carter says.
Morningstar's Parent Pillar may be underappreciated, especially for closed-end funds.
Despite the market's wild ride, most CEFs closed the year with positive share price and NAV returns.
Debt in developing markets is not as risky as some think, and closed-end funds are good vehicles to take advantage of the higher yields in these regions.
There’s more, and less, than meets the eye in momentum’s longterm track record.
Here are two favorite natural-resources funds from opposite sides of the oil patch.